DE69223638T2 - Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung - Google Patents

Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Info

Publication number
DE69223638T2
DE69223638T2 DE69223638T DE69223638T DE69223638T2 DE 69223638 T2 DE69223638 T2 DE 69223638T2 DE 69223638 T DE69223638 T DE 69223638T DE 69223638 T DE69223638 T DE 69223638T DE 69223638 T2 DE69223638 T2 DE 69223638T2
Authority
DE
Germany
Prior art keywords
lfa
antigen
treatment
presenting cells
diseases caused
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69223638T
Other languages
English (en)
Other versions
DE69223638D1 (de
Inventor
Barbara Wallner
Kevin Cooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Astellas US LLC
Original Assignee
Biogen Inc
University of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc, University of Michigan filed Critical Biogen Inc
Application granted granted Critical
Publication of DE69223638D1 publication Critical patent/DE69223638D1/de
Publication of DE69223638T2 publication Critical patent/DE69223638T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2824—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD58
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70507—CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70528—CD58
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69223638T 1991-10-07 1992-10-06 Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung Expired - Lifetime DE69223638T2 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77096991A 1991-10-07 1991-10-07
US86202292A 1992-04-02 1992-04-02
PCT/US1992/008755 WO1993006866A2 (en) 1991-10-07 1992-10-06 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the cd2/lfa-3 interaction
HK98105235A HK1006056A1 (en) 1991-10-07 1998-06-12 Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction

Publications (2)

Publication Number Publication Date
DE69223638D1 DE69223638D1 (de) 1998-01-29
DE69223638T2 true DE69223638T2 (de) 1998-05-20

Family

ID=27269909

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69223638T Expired - Lifetime DE69223638T2 (de) 1991-10-07 1992-10-06 Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung

Country Status (10)

Country Link
EP (1) EP0607332B1 (de)
JP (3) JPH07502496A (de)
AT (1) ATE161190T1 (de)
AU (1) AU677772B2 (de)
CA (1) CA2120732C (de)
DE (1) DE69223638T2 (de)
ES (1) ES2112335T3 (de)
GR (1) GR3026135T3 (de)
HK (1) HK1006056A1 (de)
WO (1) WO1993006866A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0786255T3 (da) * 1991-10-07 2002-04-15 Biogen Inc Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein
US6764681B2 (en) 1991-10-07 2004-07-20 Biogen, Inc. Method of prophylaxis or treatment of antigen presenting cell driven skin conditions using inhibitors of the CD2/LFA-3 interaction
US5795572A (en) * 1993-05-25 1998-08-18 Bristol-Myers Squibb Company Monoclonal antibodies and FV specific for CD2 antigen
ES2153895T3 (es) * 1994-03-08 2001-03-16 Dana Farber Cancer Inst Inc Metodos para modular la insensibilidad de celulas t.
US6185457B1 (en) 1994-05-31 2001-02-06 Galvani, Ltd. Method and apparatus for electrically forcing cardiac output in an arrhythmia patient
AU1207999A (en) * 1997-10-30 1999-05-24 Brigham And Women's Hospital Control of lymphocyte localization by leep-cam activity
US6001651A (en) * 1998-03-20 1999-12-14 Isis Pharmaceuticals Inc. Antisense modulation of LFA-3
DK1086207T3 (da) 1998-06-12 2007-05-29 Sinai School Medicine Hidtil ukendte fremgangsmåder og inteferon-deficiente substrater til opformering af vira
EP1409015A4 (de) * 2001-02-01 2006-04-12 Biogen Idec Inc Verfahren zur behandlung oder vorbeugung von hauterkrangungen unter verwendung von cd2-bindungsagenzien
EP1419236A4 (de) 2001-07-24 2005-08-03 Biogen Idec Inc Verfahren zur behandlung von sklerotischen erkrankungen unter verwendung cd2-bindender substanzen
WO2004022097A1 (en) * 2002-09-05 2004-03-18 Medimmune, Inc. Methods of preventing or treating cell malignancies by administering cd2 antagonists
JP4764818B2 (ja) 2003-04-11 2011-09-07 メディミューン，エルエルシー 組換えｉｌ−９抗体およびその使用
EP1718333A2 (de) * 2004-02-02 2006-11-08 Schering Corporation Verfahren zur modulation von cd200 und cd200r
CA2565259A1 (en) 2004-05-07 2005-12-08 Astellas Us Llc Soluble lfa-3 polypeptide for treating viral disorders
BRPI0511776B1 (pt) 2004-06-01 2016-11-29 Sinai School Medicine vírus atenuado de influenza de suínos geneticamente engenheirado, formulação imunogênica, formulação farmacêutica, uso da formulação imunogênica, uso do vírus atenuado de influenza de suínos geneticamente engenheirado, uso da formulação farmacêutica e método para produzir uma vacina, uma formulação imunogênica ou uma formulação farmacêutica
WO2006034334A2 (en) 2004-09-21 2006-03-30 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peptide analogs capable of enhancing stimulation of a glioma-specific ctl response
US8137676B2 (en) 2005-02-15 2012-03-20 Mount Sinai School Of Medicine Genetically engineered equine influenza virus and uses thereof
US8483822B1 (en) 2009-07-02 2013-07-09 Galvani, Ltd. Adaptive medium voltage therapy for cardiac arrhythmias
CA2809362C (en) 2010-08-24 2020-03-10 University Of Pittsburgh - Of The Commonwealth System Of Higher Educatn Interleukin-13 receptor alpha 2 peptide-based brain cancer vaccines
US8658128B2 (en) 2011-02-03 2014-02-25 Pop Test Cortisol Llc System and method for diagnosis and treatment
EP2828664B1 (de) 2012-03-19 2018-09-26 Stemline Therapeutics Inc. Verfahren zur behandlung und überwachung eines karzinomstatus
PT3536334T (pt) 2012-05-16 2021-09-27 Stemline Therapeutics Inc Vacinas contra o cancro dirigidas a células estaminais cancerígenas
US8750990B1 (en) 2012-12-12 2014-06-10 Galvani, Ltd. Coordinated medium voltage therapy for improving effectiveness of defibrillation therapy
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
EP3261664A1 (de) 2015-02-26 2018-01-03 Boehringer Ingelheim Vetmedica GmbH Bivalenter schweineinfluenzavirusimpfstoff

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT503648E (pt) * 1991-03-12 2000-10-31 Biogen Inc Dominio do antigenio 3 associado a funcao linfocitica de ligacao as cd2
AU1771192A (en) * 1991-03-12 1992-10-21 Biogen, Inc. Monoclonal antibodies recognizing lymphocyte function associated antigen-3
DK0786255T3 (da) * 1991-10-07 2002-04-15 Biogen Inc Fremgangsmåde til forbedring af tolerancen for allotransplantater og xenotransplantater ved administration af et LFA-3- eller CD2-bindingsprotein

Also Published As

Publication number Publication date
JP2005015493A (ja) 2005-01-20
HK1006056A1 (en) 1999-02-05
WO1993006866A2 (en) 1993-04-15
EP0607332A1 (de) 1994-07-27
GR3026135T3 (en) 1998-05-29
AU2890892A (en) 1993-05-03
JPH07502496A (ja) 1995-03-16
WO1993006866A3 (en) 1993-08-05
JP2003137810A (ja) 2003-05-14
EP0607332B1 (de) 1997-12-17
AU677772B2 (en) 1997-05-08
DE69223638D1 (de) 1998-01-29
CA2120732A1 (en) 1993-04-15
ES2112335T3 (es) 1998-04-01
ATE161190T1 (de) 1998-01-15
CA2120732C (en) 2008-09-16

Similar Documents

Publication Publication Date Title
DE69223638D1 (de) Vorbeugungsmethode oder behandlung von, durch antigen-präsentierende zellen hervorgerufene, hautkrankheiten mittels inhibitoren der cd2/lfa-3 wechselwirkung
JP2008503295A (ja) 電磁放射線の美容における使用
ATE252868T1 (de) Vorrichtung für elektrophysiologische behandlungen des herzens
UY26249A1 (es) Moléculas pequenas útiles en el tratamiento de las enfermedades inflamatorias ley 17164 art. 127
ATE132762T1 (de) Vorrichtung zur behandlung von entzündlichen, sich im anfangsstadium befindlichen hautveränderungen
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE602005016198D1 (de) Verwendung von Hülsenfrüchten zur Herstellung von Produkten zum Schutz oder Behandlung von radiotherapie-bedingten Hautschäden
NO20051681L (no) Lysaldring av hud og aktinskadebehandling
DE69719495T2 (de) Verwendung von inhibitoren der retinsäureaktivität zur behandlung empfindliche r haut und/oder durch uv-strahlung hervorgerufener akuter schädigungen
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
EA200400951A1 (ru) Способ и процесс создания моложавой, гладкой кожи с малым количеством пор
TR200201608T3 (tr) Deride, saçta serbest radikal polimerlerleşmenin önlenmesi için yöntemler, bileşikler
Zeredo et al. Antinociceptive effect of Er: YAG laser irradiation in the orofacial formalin test
DE59907195D1 (de) Verfahren zur behandlung von erkrankungen oder störungen des innenohrs
DE69717495D1 (de) Verwendung eines terminalia catappa extraktes
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
Kang et al. A split-face study evaluating the efficacy of a topical antioxidant cream containing tocotrienol after 1064-nm picosecond Nd: YAG laser treatment for environment-induced skin pigmentation
DE69628153D1 (de) Verwendung von natriumchlorid zur behandlung der akne und/oder der rosacea
DE602004016292D1 (de) Verwendung einer zusammensetzung mit vitamin k1-oxid oder einem derivat daraus zur behandlung und/oder vorbeugung von hautverletzungen bei säugern
NO307088B1 (no) Nye cardiobeskyttende midler
ATE365718T1 (de) Substituierte 11-phenyl-dibenzazepin-verbindungen,die nützlich sind zur behandlung oder vorbeugung von durch abnormale zellproliferation gekennzeichneten krankheiten
DE69231968T2 (de) Behandlung eines durch uv-strahlung verursachten erythems
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: BIOGEN IDEC MA INC., CAMBRIDGE, MASS., US

Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ANN ARB

8327 Change in the person/name/address of the patent owner

Owner name: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, ANN, US

Owner name: ASTELLAS US LLC, DEERFIELD, ILL., US

R071 Expiry of right

Ref document number: 607332

Country of ref document: EP